Multicenter, Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group, Ambulatory Safety and Efficacy Study of ARK-E021 Topical Foam of 5% and 10% in Subjects With Mild to Moderate Acne Vulgaris
Latest Information Update: 20 May 2021
At a glance
- Drugs ARK-E021 (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions; Therapeutic Use
- Sponsors M Arkin 1999 Ltd
- 07 Dec 2013 New trial record